Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Difference in Immunogenic Responses to COVID-19 Vaccines in Patients With Cancer Receiving Chemotherapy Versus Nonchemotherapy Treatment.
Tantiyavarong W, Sungkasubun P, Chaiwiriyawong W, Supavavej A, Limpawittayakul P, Weerasubpong B, Siripaibun J, Phanthunane C, Lamlertthon W, Ungtrakul T, Tawinprai K, Tantiyavarong P, Samdaengpan C. Tantiyavarong W, et al. Among authors: samdaengpan c. JCO Glob Oncol. 2023 Feb;9:e2200331. doi: 10.1200/GO.22.00331. JCO Glob Oncol. 2023. PMID: 36821802 Free PMC article.
Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital.
Limpawittayakul P, Sungkasubun P, Chaiwiriyawong W, Supavavej A, Weerasubpong B, Siripaibun J, Phanthunane C, Lamlertthon W, Ungtrakul T, Tawinprai K, Tantiyavarong W, Samdaengpan C. Limpawittayakul P, et al. Among authors: samdaengpan c. Hum Vaccin Immunother. 2022 Nov 30;18(6):2104058. doi: 10.1080/21645515.2022.2104058. Epub 2022 Aug 17. Hum Vaccin Immunother. 2022. PMID: 35976687 Free PMC article.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study.
Porntharukchareon T, Chartisathian W, Navinpipat M, Samdaengpan C, Cheirsilpa K, Lueprasitsakul A, Worawichawong S, Muangsillapasart V, Pumuthaivirat P, Dechates B, Sirisreetreerux S, Siripongboonsitti T, Rangsrisaeneepitak V, Jirawattanapalin K, Tawinprai K. Porntharukchareon T, et al. Among authors: samdaengpan c. Hum Vaccin Immunother. 2023 Aug 1;19(2):2251850. doi: 10.1080/21645515.2023.2251850. Hum Vaccin Immunother. 2023. PMID: 37671943 Free PMC article.